Semnur Pharmaceuticals Files 8-K
Ticker: SMNRW · Form: 8-K · Filed: Dec 3, 2025 · CIK: 1913577
| Field | Detail |
|---|---|
| Company | Semnur Pharmaceuticals, Inc. (SMNRW) |
| Form Type | 8-K |
| Filed Date | Dec 3, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $11.50 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, corporate-event, pharmaceuticals
TL;DR
Semnur Pharma filed an 8-K on Dec 3, 2025. Formerly Denali Capital.
AI Summary
Semnur Pharmaceuticals, Inc. filed an 8-K on December 3, 2025, reporting other events and financial statements. The company, formerly known as Denali Capital Acquisition Corp. until February 24, 2022, is incorporated in Delaware and headquartered in Palo Alto, California.
Why It Matters
This filing indicates Semnur Pharmaceuticals is making a regulatory submission, which could signal significant corporate events or financial updates.
Risk Assessment
Risk Level: low — This is a routine filing for an 8-K, indicating a corporate event or financial update without immediate negative or positive implications.
Key Players & Entities
- Semnur Pharmaceuticals, Inc. (company) — Registrant
- Denali Capital Acquisition Corp. (company) — Former company name
- December 3, 2025 (date) — Date of report
- February 24, 2022 (date) — Date of name change
- Palo Alto, California (location) — Principal executive offices
FAQ
What specific 'Other Events' are being reported in this 8-K filing?
The provided text does not detail the specific 'Other Events' beyond stating it is an item being reported in the 8-K.
What is the primary business of Semnur Pharmaceuticals, Inc.?
Semnur Pharmaceuticals, Inc. is classified under the Standard Industrial Classification code 2834, which corresponds to Pharmaceutical Preparations.
When did Semnur Pharmaceuticals, Inc. change its name from Denali Capital Acquisition Corp.?
The company changed its name from Denali Capital Acquisition Corp. on February 24, 2022.
Where are Semnur Pharmaceuticals, Inc.'s principal executive offices located?
The principal executive offices are located at 960 San Antonio Road, Palo Alto, California, 94303.
What is the Commission File Number for Semnur Pharmaceuticals, Inc.?
The Commission File Number for Semnur Pharmaceuticals, Inc. is 001-41351.
Filing Stats: 617 words · 2 min read · ~2 pages · Grade level 11.7 · Accepted 2025-12-03 16:20:34
Key Financial Figures
- $0.0001 — ich registered Common stock, par value $0.0001 per share SMNR * Warrants to purc
- $11.50 — mon stock, each at an exercise price of $11.50 per share SMNRW * * On April 16,
Filing Documents
- d42925d8k.htm (8-K) — 28KB
- d42925dex41.htm (EX-4.1) — 75KB
- 0001193125-25-306757.txt ( ) — 292KB
- smnr-20251203.xsd (EX-101.SCH) — 3KB
- smnr-20251203_def.xml (EX-101.DEF) — 16KB
- smnr-20251203_lab.xml (EX-101.LAB) — 26KB
- smnr-20251203_pre.xml (EX-101.PRE) — 17KB
- d42925d8k_htm.xml (XML) — 8KB
Description of Securities
Description of Securities 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SEMNUR PHARMACEUTICALS, INC. By: /s/ Jaisim Shah Name: Jaisim Shah Title: Chief Executive Officer and President Date: December 3, 2025